PARP 抑制剂作为酪氨酸激酶依赖型白血病的治疗选择：综述。
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review.
机构信息
Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil
出版信息
Anticancer Res. 2020 Jun;40(6):3055-3063. doi: 10.21873/anticanres.14286.
The idea of utilizing poly-ADP-ribose polymerase inhibitors (PARPi) as therapeutics for cancer has grown in popularity since its original approval for clinical usage in treatment of BRCA DNA repair-associated-mutated ovarian cancer. In this study, we evaluated experimental data regarding in vitro studies utilizing PARPi as a treatment for tyrosine kinase (TK)-dependent leukemia. Studies from 2015 to 2019 were compiled and the ones with most relevant TK pathways and PARP inhibition were analyzed. PARPi showed activity against many leukemia cell lines and samples from patients with primary leukemia, especially when combined with other signaling pathway inhibitor drugs, improving upon the hypothesis that the utilization of PARPi has potential as a new therapeutic approach in treatment of primary leukemia and TK-dependent leukemia.
自从聚二磷酸腺苷核糖聚合酶抑制剂（PARPi）最初被批准用于治疗 BRCA 相关 DNA 修复突变型卵巢癌以来，其作为癌症治疗药物的理念越来越受到关注。在这项研究中，我们评估了有关利用 PARPi 作为酪氨酸激酶（TK）依赖性白血病治疗的体外研究的实验数据。汇编了 2015 年至 2019 年的研究，并分析了与最相关的 TK 途径和 PARP 抑制相关的研究。PARPi 对许多白血病细胞系和原发性白血病患者的样本均具有活性，尤其是与其他信号通路抑制剂药物联合使用时，这进一步证实了PARPi 的应用具有作为原发性白血病和 TK 依赖性白血病治疗新疗法的潜力的假设。
Zotero 插件